Sera Prognostics, Inc.
SERA
NASDAQ·Healthcare·Medical - Diagnostics & Research·Mkt cap $77.1M
$2.02
▲ +2.02%
P/E
-5.77
Mkt Cap
$77.1M
52-Wk Range
$1.56–$3.95
52-Week Range
$1.56 - $3.95
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 36.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Average volatility.
Growth
Strong growth ahead
Value
Deep value opportunity - significant discount to sector peers
Momentum
Weak
-11.8% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying SERA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 12, 2026
AUG 12, 2026
Reported EPS of -$0.18 vs -$0.15 consensus (-16.7% surprise). Revenue of $30.0K vs $71.4K expected (-58.0%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-16.7%
Revenue trend · last 2Q
—
+76%
Q1 26
Q2 26
$14.0K
$30.0K
Margins · last 2Q
Gross
-66.7%
Profit
-30463.3%
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Craig-Hallum · Jun 4, 2026
vs Industry
How SERA stacks vs Medical - Diagnostics & Research
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.